Repotrex 40 Mg (Repotrectinib) Capsules

Introduction

Repotrex 40 mg (Repotrectinib) is a next-generation, potent, and highly selective tyrosine kinase inhibitor (TKI). Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, this medication is a breakthrough in the treatment of cancers driven by ROS1 and NTRK gene fusions. Repotrex is specifically engineered as a compact macrocycle, allowing it to overcome resistance mutations that often render earlier-generation inhibitors ineffective. Its superior ability to penetrate the central nervous system (CNS) makes it a vital option for patients with intracranial metastases.

Indications

Repotrex 40 mg (Repotrectinib) is indicated for:

ROS1-Positive NSCLC: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.
NTRK-Positive Solid Tumors: Treatment of adult and pediatric patients (12 years and older) with solid tumors that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, are metastatic, or where surgical removal is likely to result in severe complications.

Pharmacology

Repotrectinib, the active ingredient in Repotrex, is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 and tropomyosin receptor tyrosine kinases (TRKs).

Mechanism: It binds to the ATP-binding site of the kinase domain. Its “compact” design minimizes steric hindrance, allowing it to remain effective even in the presence of common “gatekeeper” resistance mutations (such as ROS1 G2032R).
CNS Activity: Due to its low molecular weight and specific structure, it achieves high concentrations in the brain, effectively targeting secondary tumors in the central nervous system.

Dosage & Administration

Oral Administration for Adults and Pediatrics (12+):

Step-up Dosing (Days 1–14): 160 mg (four 40 mg capsules) taken orally once daily.
Maintenance Phase (Day 15 onwards): Increase to 160 mg (four 40 mg capsules) taken orally twice daily.
Administration: Swallow capsules whole. Do not open, crush, or chew. Can be taken with or without food.
Missed Dose: If a dose is missed, take it as soon as possible. If it is within 6 hours of the next scheduled dose, skip the missed dose.

Drug Interactions

Strong/Moderate CYP3A Inhibitors: May increase Repotrectinib levels; avoid co-administration or adjust the dose as directed.
Strong/Moderate CYP3A Inducers: May significantly reduce the effectiveness of the drug.
Hormonal Contraceptives: Repotrex may reduce the efficacy of birth control pills; use of non-hormonal methods is required.
Grapefruit: Avoid consuming grapefruit or grapefruit juice during treatment.

Contraindications

Hypersensitivity: Known hypersensitivity to Repotrectinib or any inactive ingredients in the capsule.
Pregnancy: Not recommended due to the potential for severe fetal harm.

Side Effects

Patients receiving Repotrex 40 mg may experience:

Neurological: Dizziness (most common), ataxia (coordination issues), and cognitive impairment (confusion or memory issues).
Sensory: Dysgeusia (distortion of the sense of taste) and paresthesia.
Gastrointestinal: Constipation and nausea.
Systemic: Fatigue, dyspnea (shortness of breath), and muscular weakness.

Pregnancy & Lactation

Pregnancy: Females of reproductive potential must use effective non-hormonal contraception during treatment and for 2 months after the final dose.
Lactation: Breastfeeding is not recommended during therapy and for at least 10 days following the last dose.

Precautions & Warnings

CNS Effects: Due to the risk of dizziness and cognitive changes, patients should use caution when driving or operating heavy machinery.
Pneumonitis: Monitor for new or worsening respiratory symptoms. Discontinue if Interstitial Lung Disease (ILD) is suspected.
Hepatotoxicity: Regular monitoring of liver enzymes (ALT/AST) is required, particularly during the first two months of treatment.
Uric Acid Levels: Monitor for hyperuricemia (high uric acid), especially in patients with a history of gout.

Use in Special Populations

Pediatric Use: Safety is established for children aged 12 and older with NTRK-positive solid tumors.
Hepatic Impairment: Not recommended for use in patients with moderate to severe hepatic impairment.

Overdose Effects

Symptoms of overdose may include severe dizziness, confusion, or gastrointestinal distress. Management involves immediate supportive care and clinical monitoring.

Storage

Conditions: Store at controlled room temperature (20°C to 25°C).
Protection: Keep in the original container to protect from light and moisture. Keep out of reach of children.

Supplier Information

Orio Pharma is a trusted global provider of advanced oncology solutions. We specialize in the efficient distribution of high-tech medicines like Repotrex 40 mg, ensuring that patients worldwide have access to the latest innovations in cancer care. For wholesale and international supply inquiries, please contact our export division.

Manufacturer Information

Repotrex 40 mg is manufactured by Everest Pharmaceuticals Ltd., a premier pharmaceutical company in Bangladesh dedicated to the production of high-quality, targeted oncology generics and life-saving medications.